In a blow to tens of thousands of Brits, draft guidance by the NHS spending watchdog ruled the benefits of the drug are far too small to justify the roll-out cost. In a blow to tens of thousands of Brits, draft guidance by the NHS spending watchdog ruled the benefits of the drug are far too small to justify the roll-out cost.
Anger as NHS patients told they WON’T get ‘new hope’ Alzheimer’s drug donanemab
